ServiceNow, Live Nation Entertainment And A Health Care Stock: CNBC's 'Final Trades' - Live Nation Entertainment ( NYSE:LYV ) , Bristol-Myers Squibb ( NYSE:BMY )
Jenny Van Leeuwen Harrington says Bristol-Myers Squibb has a 5.5% dividend yield and has paid dividends for 55 straight years. Malcolm Ethridge says ServiceNow is around 25% off its 52-week high. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here →
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Medtronic ( NYSE:MDT ) , Bristol-Myers Squibb ( NYSE:BMY )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Will AI's Diversification Beyond Oil & Gas Fuel Its Next Growth Phase?
C3.ai is driving growth beyond oil and gas, with rising traction in manufacturing, government and life sciences in fiscal 2025.
How Do Investors Really Feel About Bristol-Myers Squibb? - Bristol-Myers Squibb ( NYSE:BMY )
Bristol-Myers Squibb's BMY short percent of float has fallen 19.58% since its last report. The company recently reported that it has 30.92 million shares sold short, which is 1.52% of all regular shares that are available for trading.
Investors Heavily Search Bristol Myers Squibb Company ( BMY ) : Here is What You Need to Know
Bristol Myers (BMY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Price Over Earnings Overview: Bristol-Myers Squibb - Bristol-Myers Squibb ( NYSE:BMY )
Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $48.48, after a 0.08% increase. Moreover, over the past month, the stock went up by 0.96%, but in the past year, fell by 1.02%.
The Zacks Analyst Blog Highlights Lowe's, Bristol-Myers Squibb, Marvell Technology and Kewaunee Scientific
Zacks spotlights Lowe's, Bristol Myers, Marvell, and Kewaunee Scientific as earnings, strategy, and acquisitions shape growth outlooks.
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS - Amgen ( NASDAQ:AMGN )
Greenlight Capital shifts its portfolio, betting on construction and fashion while parting ways with medical imaging. Einhorn's hedge fund optimizes its investment strategy, signaling confidence in new picks and skepticism in former holdings.
Century Reports Flat Loss in Fiscal Q2
Century Therapeutics ( NASDAQ:IPSC ) , an early-stage biotechnology company pioneering cell therapies using induced pluripotent stem cell ( iPSC ) technology, reported its second quarter 2025 financial results on August 14, 2025, for the period ending June 30.
Want Over $2,100 in Annual Dividends? Invest $12,000 Into Each of These 3 High-Yielding Stocks
The dividend stocks listed below all yield more than 5% and look like safe long-term buys.
Can This Beaten-Down Stock Bounce Back?
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership - X4 Pharmaceuticals ( NASDAQ:XFOR )
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership - X4 Pharmaceuticals ( NASDAQ:XFOR )
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chief Financial Officer
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates ...
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
Clinical Trials of Budoprutug in Immune Thrombocytopenia ( ITP ) and Systemic Lupus Erythematosus ( SLE ) Underway. Trial of Budoprutug in Primary Membranous Nephropathy ( pMN ) Expected to Initiate in the Coming Weeks ...
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
HUNTSVILLE, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Serina Therapeutics, Inc. ( "Serina" ) ( NYSE American: SER ) , a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization ...
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - AstraZeneca ( NASDAQ:AZN ) , Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY ) , Sanofi ( NASDAQ:SNY )
Four drugmakers are accused of coordinating to limit mandated discounts for safety-net clinics. Appeals court says plaintiffs plausibly alleged a price-fixing conspiracy. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
C3.ai's Generative AI Surge: A Catalyst for Fiscal 2026 Upside?
AI's fiscal 2025 momentum, fueled by surging Generative AI deployments, sets the stage for projected double-digit revenue growth in 2026.
Repare ( RPTX ) Q2 Loss Narrows 52%
Repare Therapeutics ( NASDAQ:RPTX ) , a clinical-stage precision oncology company, released its second quarter 2025 earnings on August 8, 2025. The most notable news from the release was its GAAP net loss per share of $0.39, a much narrower loss than the consensus GAAP estimate of -$0.56.
CytomX ( CTMX ) Q2 Revenue Drops 26%
CytomX Therapeutics ( NASDAQ:CTMX ) , a biotechnology company focused on developing targeted oncology therapies, reported its second quarter 2025 results on August 7, 2025. In the period, the most significant developments included a year-over-year decline in GAAP revenue, improvements in cost ...
Avidity ( RNA ) Q2 Revenue Jumps 88%
Avidity Biosciences ( NASDAQ:RNA ) , a biotechnology firm developing RNA-targeted therapeutics for rare muscle diseases, reported its second-quarter 2025 results on August 7, 2025. The period featured sharply higher revenue ( GAAP ) at $3.8 million, well above the $1.49 million average analyst ...
CYTK Earnings Jump 3,065%
Cytokinetics ( NASDAQ:CYTK ) , a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic outperformance on GAAP revenue: it booked $66.8 million in GAAP revenue, compared to analyst expectations of ...
PRME Revenue Misses by 73%
Prime Medicine ( NASDAQ:PRME ) , a genetic medicine innovator developing next-generation gene editing therapies, released its second quarter 2025 earnings on August 7, 2025. The company reported GAAP revenue of $1.1 million, substantially below analyst estimates of $4.18 million and driven solely ...
Replimune ( REPL ) Q1 Loss Widens 61%
Replimune Group ( NASDAQ:REPL ) , a biotechnology company specializing in oncolytic immunotherapies for cancer, reported its earnings for the first quarter of fiscal 2026 on August 7, 2025. The most notable headline was the U.S.
Eli Lilly, Amgen In Legal Fight Over Drug Discount Program - Eli Lilly ( NYSE:LLY ) , Amgen ( NASDAQ:AMGN )
Amgen, Eli Lilly, and UCB allege HHS wrongly certified ineligible clinics under 340B. A federal court denied HHS's motion to dismiss key parts of the lawsuit. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday.
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
1 Small-Cap Biotech Stock Poised for a Breakout
This developmental biotech is nearing a key inflection point.
Sensei ( SNSE ) Q2 Loss Narrows 31%
Sensei Biotherapeutics ( NASDAQ:SNSE ) is a clinical-stage immunotherapy company developing innovative antibody treatments for cancer. On August 5, 2025, it reported financial results for the second quarter of 2025. The key news was that loss per share was $ ( 3.91 ) in Q2 2025 ( GAAP ) , which ...
Prothena Q2 Revenue Drops 97%
Prothena ( NASDAQ:PRTA ) , a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker-than-expected performance, with GAAP EPS of -2.34 missing the analysts' estimate of -1.25 ...
Bristol Myers Squibb Company ( BMY ) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Is Replimune Stock Trading Lower On Monday? - Replimune Group ( NASDAQ:REPL )
Replimune shares plunged nearly 43% in the past month following FDA's rejection of its cancer drug. Daily volume surged to 15.9 million vs. 7.9 million average as a lawsuit alleged misleading statements over the IGNYTE trial. The market's back, and these 3 income stocks are thriving. See them here→
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - BioNTech ( NASDAQ:BNTX )
BioNTech reported Q2 sales of $295.7 million, beating expectations of $147.9 million. Per-share loss narrowed to $1.82 vs. the consensus loss of $2.42. The next correction is closer than you think. Find out how Tom Gentile plans to trade it, live on Wednesday.
This Biotech Stock Could Soar on Upcoming Clinical Data
This weight loss drugmaker may be significantly undervalued right now.
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT ( 2:00 p.m. CEST ...
Chinese drug start-ups poised for 2025 profits, in industry milestone
A pair of Hong Kong-listed mainland Chinese biotechnology firms are poised to turn a profit this year as their revenue from novel drugs finally outstrips costs related to research and development and marketing, according to analysts.
Bristol Myers ( BMY ) Q2 EPS Jumps 36%
Bristol Myers Squibb ( NYSE:BMY ) is a leading biopharmaceutical company focused on innovative medicines in oncology, cardiovascular, immunology, and neuroscience. On July 31, 2025, it released results for the second quarter, reporting GAAP revenue and non-GAAP EPS that exceeded Wall Street ...
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' - AbbVie ( NYSE:ABBV ) , Amgen ( NASDAQ:AMGN )
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. ArrivedBuy shares of homes and vacation rentals for as little as $100. Get Started
Bristol-Myers Squibb Unusual Options Activity For July 31 - Bristol-Myers Squibb ( NYSE:BMY )
Investors with a lot of money to spend have taken a bullish stance on Bristol-Myers Squibb BMY. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View
BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.
PCE Comes in Warmer Than Expected
Pre-market futures are in the green this morning and holding steady - all but the small-cap Russell 2000, which is currently trading down half of one percent. The Dow is up +115 points, the S&P 500 is +60 and the Nasdaq is up a strong +320 points at this hour. Bond yields are also ticking up ...
Economy Heating Up on PCE for June
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
Why Is Bristol Myers Stock Falling Thursday? - Bristol-Myers Squibb ( NYSE:BMY )
Q2 revenue rose to $12.27 billion, beating estimates; EPS of $1.46 missed the $1.58 consensus. 2025 EPS guidance cut to $6.35-$6.65; sales outlook raised to $46.5 billion-$47.5 billion. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Bristol Myers Squibb ( BMY ) Q2 Earnings and Revenues Top Estimates
Bristol Myers (BMY) delivered earnings and revenue surprises of +36.45% and +7.67%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday - Apple ( NASDAQ:AAPL ) , Amazon.com ( NASDAQ:AMZN )
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Apple Inc. AAPL to report quarterly earnings at $1.42 per share on revenue of $89.04 billion after the closing bell, according to data from ...
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Got $500? 3 Blue Chip Dividend Stocks to Buy and Hold Forever
Being a great investor doesn't have to be complicated or expensive.
Trump's pharmaceutical tariffs could affect some drugmakers more than others
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.
Altanine Names Charles J. Andres, Ph.D., J.D., as CEO to Lead Clinical and Strategic Expansion
LOS ANGELES, July 29, 2025 ( GLOBE NEWSWIRE ) -- Altanine, Inc., a pharmaceutical company advancing proprietary drug delivery technologies across high-growth therapeutic areas, today announced the appointment of Charles J. Andres, Ph.D., J.D., as its new Chief Executive Officer.
